Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind comparison of two AS03A-adjuvanted A/California/7/2009 (H1N1)v-like influenza vaccine manufacturing processes in adults
2009-015997-36Phase 3Completed
- Sponsor
- GSK
- Start
- Sep 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Q-Pan H1N1 in influenza A virus infection (H1N1) (2 arms), sponsored by GSK. Primary endpoints: Humoral immune response in terms of Haemagglutination Inhibition (HI) antibodies, Immunological non-inferiority 21 days after first vaccination and 1 more. Started Sep 2009; status: completed.
02
Drugs
Q-Pan H1N1
03
Conditions
influenza A virus infection (H1N1)
Beyond the preview
Go deeper on 2009-015997-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015997-36.